Cardiology Research and Practice contrast agent after cardiac catheterization. A prospective trial,” Annals of Internal Medicine, vol. 110, no. 2, pp. 119– 124, 1989. [28] P. A. McCullough, A. Adam, C. R. Becker et al., “Risk predic- tion of contrast-induced nephropathy,” American Journal of Cardiology, vol. 98, no. 6, pp. 27–36, 2006. [29] P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and W. W. O’Neill, “Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality,” American Journal of Medicine, vol. 103, no. 5, pp. 368–375, 1997. [30] E. Nikolsky, E. D. Aymong, G. Dangas, and R. Mehran, “Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function,” Reviews in Cardiovascular Medicine, vol. 4, supplement 1, pp. S7–S14, 2003. [31] S. M. Bagshaw and B. F. Culleton, “Contrast-induced nephropathy: epidemiology and prevention,” Minerva Car- dioangiologica, vol. 54, no. 1, pp. 109–129, 2006. [32] O. Toprak, M. Cirit, M. Yesil et al., “Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 22, no. 3, pp. 819– 826, 2007. [33] A. S. Berns, “Nephrotoxicity of contrast media,” Kidney International, vol. 36, no. 4, pp. 730–740, 1989. [34] G. Marenzi, G. Lauri, E. Assanelli et al., “Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1780–1785, 2004. [35] R. Mehran, E. D. Aymong, E. Nikolsky et al., “A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation,” Journal of the American College of Cardiology, vol. 44, no. 7, pp. 1393–1399, 2004. [36] J. K. Kahn, B. D. Rutherford, D. R. McConahay et al., “High- dose contrast agent administration during complex coronary angioplasty,” American Heart Journal, vol. 120, no. 3, pp. 533– 536, 1990. [37] M. A. Rosovsky, H. Rusinek, A. Berenstein, S. Basak, A. Setton, and P. K. Nelson, “High-dose administration of nonionic contrast media: a retrospective review,” Radiology, vol. 200, no. 1, pp. 119–122, 1996. [38] G. C. Kane, B. J. Doyle, A. Lerman, G. W. Barsness, P. J. Best, and C. S. Rihal, “Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography,” Journal of the American College of Cardiology, vol. 51, no. 1, pp. 89–90, 2008. [39] S. F. Mekan, M. A. Rabbani, M. Azhar-Uddin, and S. S. Ali, “Radiocontrast nephropathy: is it dose related or not?” Journal of the Pakistan Medical Association, vol. 54, no. 7, pp. 372–374, 2004. [40] W. K. Laskey, C. Jenkins, F. Selzer et al., “Volume-to- creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after per- cutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 50, no. 7, pp. 584–590, 2007. [41] B. J. Barrett and E. J. Carlisle, “Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated con- trast media,” Radiology, vol. 188, no. 1, pp. 171–178, 1993. [42] M. R. Rudnick, S. Goldfarb, L. Wexler et al., “Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a 9 randomized trial. The Iohexol Cooperative Study,” Kidney International, vol. 47, pp. 254–261, 1995. [43] P. Aspelin, P. Aubry, S.-G. Fransson, R. Strasser, R. Wil- lenbrock, and K. J. Berg, “Nephrotoxic eﬀects in high-risk patients undergoing angiography,” New England Journal of Medicine, vol. 348, no. 6, pp. 491–499, 2003. [44] P. A. McCullough, M. E. Bertrand, J. A. Brinker, and F. Stacul, “A meta-analysis of the renal safety of isosmolar Iodixanol compared with low-osmolar contrast media,” Journal of the American College of Cardiology, vol. 48, no. 4, pp. 692–699, 2006. [45] S.-H. Jo, T.-J. Youn, B.-K. Koo et al., “Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insuﬃciency undergoing coronary angiography. The recover study: a randomized controlled trial,” Journal of the American College of Cardiology, vol. 48, no. 5, pp. 924–930, 2006. [46] R. Mehran, “ICON—a prospective, randomized, placebo- controlled trial of ioxaglate vs iodixanol in patients at increased risk for contrast nephropathy,” TCT, 2006. [47] R. J. Solomon, M. K. Natarajan, S. Doucet et al., “Car- diac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease,” Circu- lation, vol. 115, no. 25, pp. 3189–3196, 2007. [48] T. Nicholson and M. Downes, “Contrast nephrotoxicity and iso-osmolar contrast agents: implications of NEPHRIC,” Clinical Radiology, vol. 58, no. 9, pp. 659–660, 2003. [49] H. S. Thomsen, S. K. Morcos, C. M. Erley et al., “The ACTIVE trial: comparison of the eﬀects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomogra- phy,” Investigative Radiology, vol. 43, no. 3, pp. 170–178, 2008. [50] P. B. Persson, P. Hansell, and P. Liss, “Pathophysiology of con- trast medium-induced nephropathy,” Kidney International, vol. 68, no. 1, pp. 14–22, 2005. [51] B. A. Bartholomew, K. J. Harjai, S. Dukkipati et al., “Impact of nephropathy after percutaneous coronary intervention and a method for risk stratiﬁcation,” American Journal of Cardiology, vol. 93, no. 12, pp. 1515–1519, 2004. [52] S. H. Hou, D. A. Bushinsky, and J. B. Wish, “Hospital- acquired renal insuﬃciency: a prospective study,” American Journal of Medicine, vol. 74, no. 2, pp. 243–248, 1983. [53] E. M. Levy, C. M. Viscoli, and R. I. Horwitz, “The eﬀect of acute renal failure on mortality: a cohort analysis,” Journal of the American Medical Association, vol. 275, no. 19, pp. 1489– 1494, 1996. [54] P. J. M. Best, R. Lennon, H. H. Ting et al., “The impact of renal insuﬃciency on clinical outcomes in patients undergoing percutaneous coronary interventions,” Journal of the American College of Cardiology, vol. 39, no. 7, pp. 1113– 1119, 2002. [55] C. M. Erley, “Does hydration prevent radiocontrast-induced acute renal failure?” Nephrology Dialysis Transplantation, vol. 14, no. 5, pp. 1064–1066, 1999. [56] R. Solomon, C. Werner, D. Mann, J. D’Elia, and P. Silva, “Eﬀects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents,” New England Journal of Medicine, vol. 331, no. 21, pp. 1416– 1420, 1994. [57] M. A. Stevens, P. A. McCullough, K. J. Tobin et al., “A prospective randomized trial of prevention measures in